Human Rhinovirus Phase IIa Clinical Trial Commences
News Aug 18, 2008
Biota Holdings Limited has announced the commencement of dosing in the first Phase IIa challenge study of BTA798, an orally delivered and potent inhibitor of human rhinovirus (HRV).
HRV is the major cause of the common cold and is associated with clinical complications for patients with asthma, cystic fibrosis, chronic obstructive pulmonary disease or a compromised immune function.
The aim of the Phase IIa study is to evaluate BTA798 for the prevention (prophylaxis) of HRV infection in approximately 200 healthy volunteers. Each volunteer will be administered either placebo or one of three dose levels of BTA798 before being exposed to an experimental rhinovirus infection.
The double-blind study will be conducted in a controlled quarantine facility in the UK and will monitor the clinical endpoints of viral count and cold symptom improvement. Drug safety and pharmacokinetics will also be monitored to provide further data on BTA798.
The results of this and subsequent Phase IIa studies will be used to assist in selecting doses for treatment and prevention of HRV infection in later clinical studies.
Dosing is expected to be completed by December/January, subject to adequate enrolment rates with volunteers. The full results are expected by the end of April 2009.
New Studies Demonstrate Risk Reduction Potential of Heat-Not-Burn Tobacco Products and e-CigarettesNews
Data presented at the Society of Toxicology Annual Meeting (SOT) have demonstrated the potential of two different heat-not-burn tobacco products and e-cigarettes to reduce the risk of smoking-related diseases, in comparison to continued use of conventional cigarettes.READ MORE
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018